The News Review:
- Latent TB Treatment Saves Time Money And Lives
- Allos Therapeutics’ offering of 10.8 million common shares priced…
- Arthritis drug for diabetes patients
- DiaGenic Appoints SRL Ranbaxy Pathology Laboratories for Marketing…
Latent TB Treatment Saves Time Money And Lives
Science Daily – Science Daily (press release) – May 23, 2008
of the Respiratory Epidemiology & Clinical Research Unit at McGill University’s Montreal Chest Institute. "verall Rifampin costs about $484 less per patient treated which if we assume that four months of Rifampin has at least equal efficacy to nine months of Isoniazid represents an added savings to the health system of more than $10000 per patient prevented from developing TB disease. And because of improvements in compliance we are actually preventing more cases. This treatment can save money as well as lives. "At present two billion people are believed to have latent or dormant TB.
Allos Therapeutics’ offering of 10.8 million common shares priced…
Forbes – May 23, 2008
The company expects to receive net proceeds of $56. 6 million from the offering and plans to use the proceeds primarily for clinical and pre-clinical research and development manufacture of clinical trial materials and for working capital. The closing of the offering is expected May 29. The company has granted the underwriters a 30-day option to buy an additional 1. 62 million shares to cover over-allotments. Merrill Lynch (nyse:.
Arthritis drug for diabetes patients
Times of India – May 23, 2008
Salsalatean anti inflammatory drug used for decades to treat arthritis can in fact helpin treating type 2 diabetes by lowering blood sugar and reducinginflammation. ?These arethe first studies showing that potentially safe and tolerable doses of salsalatelower blood sugars and have other favourable effects in patients with type 2diabetes? said Dr Allison B. Goldfine lead researcher Director ofClinical Research at Joslin and Associate Professor at Harvard MedicalSchool. A previous study led bythe same team of researchers had shown that salsalate might prevent type 2diabetes. During the presentanalysis the researchers conducted two studies involving small numbers ofpatients with type 2 diabetes. ne tested salsalate on seven subjects at a doseof 4.
DiaGenic Appoints SRL Ranbaxy Pathology Laboratories for Marketing…
Earthtimes – May 23, 2008
With a network of nearly 40 Labs cum Wellness Centres and more than 750 collection centers across India they will be able to ensure the test is widely accessible. The growing awareness of breast cancer in India combined with the key advantages of the DiaGenic test should be well received by clinicians and the public alike. ” The clinical research study and commercial entry of the new breast cancer test in India was coordinated by DiaGenic’s Indian partner PAC Med Biotech Pvt. All laboratory services will be undertaken in India and provided by LabIndia Instruments Pvt.
